Evidence map›Paper›PMID 41883013›Full record

ArticleHistopathology2026

Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit.

Masashi Miyaoka, Joaquim Carreras, Yara Yukie Kikuti, Haruka Ikoma, Shunsuke Nagase, Atsushi Ito, Makoto Orita, Hiroshi Kawada, Rika Sakai, Yasuharu Sato and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Masashi MiyaokaDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Joaquim CarrerasDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.ORCID https://orcid.org/0000-0002-6129-8299
Yara Yukie KikutiDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Haruka IkomaDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Shunsuke NagaseDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.ORCID https://orcid.org/0000-0002-6130-3879
Atsushi ItoDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Makoto OritaDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.
Hiroshi KawadaDepartment of Hematology, School of Medicine, Tokai University, Isehara, Japan.
Rika SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Yasuharu SatoDepartment of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan.
Midori Filiz NishimuraDepartment of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama, Japan.ORCID https://orcid.org/0000-0002-8433-4870
Kunihiro TsukasakiDepartment of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Yoshihiro KameokaDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Masahiro YoshidaDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Akira SatouDepartment of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Seiichi KatoCenter for Clinical Pathology, Fujita Health University Hospital, Toyoake, Japan.ORCID https://orcid.org/0000-0001-9713-3691
Naoki OishiDepartment of Pathology, University of Yamanashi, Chuo, Japan.ORCID https://orcid.org/0000-0002-9365-1093
Akio SaitoDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan.
Ken SadahiraDivision of Hematology, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.
Yohei MasugiDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.ORCID https://orcid.org/0000-0002-6952-4043
Naoya NakamuraDepartment of Pathology, School of Medicine, Tokai University, Isehara, Japan.

Funding

Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and TechnologySchool of Medicine, Tokai University
6 · The paper itself

Abstract

aimsDiffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double-hit lymphoma with BCL2, DHL-BCL2) is a mature aggressive B-cell lymphoma that also includes concurrent triple hit with BCL6 translocation (TH). DHL with MYC and BCL6 (DH-BCL6) can also occur. The differences among these three DLBCL/HGBCL subtypes have not yet been definitively determined. METHODS AND

resultsThis study characterized the clinicopathological features and transcriptomic profiles of a series of 101 cases of DLBCL/HGBCL that were subclassified according to MYC, BCL2 and BCL6 FISH data, including cell-of-origin (COO)-like, molecular high-grade (MHG)-like and double-hit/dark-zone (DHIT/DZsig)-like signatures. DLBCL/HGBCL-DH-BCL2 was characterized by higher HGBCL morphology, CD10 positivity, GCB Hans's, GCB COO and MHG molecular subtype. DLBCL/HGBCL-TH had higher LDH levels and worse overall survival. DLBCL/HGBCL-DH-BCL6 had higher MUM1 expression, non-GCB Hans', ABC/Unclassified COO, non-MHG and low DHIT/DZ signatures. Transcriptomic analysis showed that DLBCL/HGBCL-DH-BCL2 and DLBCL/HGBCL-TH were close but separated from DLBCL/HGBCL-DH-BCL6. Gene set enrichment analysis (GSEA) revealed different levels of enrichment between the subtypes.

conclusionsDLBCL/HGBCL-DH-BCL6 differs from the DLBCL/HGBCL-DH-BCL2, and the DLBCL/HGBCL-TH is associated with the worst survival. Analysis of all three genes of MYC, BCL2 and BCL6 is recommended in the context of DLBCL/HGBCL diagnosis.

Indexed as

Lymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycAdultAgedAged, 80 and overFemaleGene Expression ProfilingGene RearrangementHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedTranscriptomeYoung AdultBCL2 protein, humanBCL6 protein, humanMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycBCL2BCL6high‐grade B‐cell lymphomamolecular profileMYCrearrangements

Identifiers

PMID41883013
PMCPMC13128323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.